Frazier reloads with $1.4B to bet on 'growth buyout' plays — nearly double the last fund

Amber Tong

The private equity arm of Frazier Healthcare Partners has collected $1.4 billion for its latest haul, muscling up a growth buyout fund to search for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Frazier reloads with $1.4B to bet on 'growth buyout' plays — nearly double the last fund

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Is there still hope for Summit's cancer drug buried in the data?

Biopharma leaders carving a path for the industry’s LGBTQ+ community

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

At a crossroads, biotechs are passing on reverse mergers in 2025

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Fra­zier re­loads with $1.4B to bet on 'growth buy­out' plays — near­ly dou­ble the last fund

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Frazier reloads with $1.4B to bet on 'growth buyout' plays — nearly double the last fund